Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy

MUC1, the transmembrane glycoprotein Mucin 1, is usually found to be overexpressed in a variety of epithelial cancers playing an important role in disease progression. MUC1 isoforms such as MUC1/Y, which lacks the entire variable number of tandem repeat region, are involved in oncogenic processes by...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 13; no. 8; p. 1239
Main Authors Khan, Huma, Makwana, Vaidehi, Santos, Sofia Nascimento dos, Bonacossa de Almeida, Carlos Eduardo, Santos-Oliveira, Ralph, Missailidis, Sotiris
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 11.08.2021
MDPI
Subjects
Amino acids
aptamer
cancer
Chromatography
Cytokines
MUC1/Y
Ovarian cancer
Peptides
pharmacokinetics
Proteins
Signal transduction
therapy
Tumors
United Kingdom > UK
Online AccessGet full text

Cover

More Information
Summary:MUC1, the transmembrane glycoprotein Mucin 1, is usually found to be overexpressed in a variety of epithelial cancers playing an important role in disease progression. MUC1 isoforms such as MUC1/Y, which lacks the entire variable number of tandem repeat region, are involved in oncogenic processes by enhancing tumour initiation. MUC1/Y is therefore considered a promising target for the identification and treatment of epithelial cancers; but so far, the precise role of MUC1/Y remains to be elucidated. In this work, we developed and identified a DNA aptamer that specifically recognizes the splice variant MUC1/Y for the first time. The DNA aptamer could bind to a wide variety of human cancer cells, and treatment of MUC1/Y positive cells resulted in reduced growth in vitro. Moreover, MUC1/Y aptamer inhibited the tumour growth of breast cancer cells in vivo. The present study highlights the importance of targeting MUC1/Y for cancer treatment and unravels the suitability of a DNA aptamer to act as a new therapeutic tool.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Current Address: BSI, Milton Keynes MK5 8PP, UK.
Current Address: Syneos Health Clinical Solutions, Milton Keynes MK8 0ES, UK.
ISSN:1999-4923
1999-4923
DOI:10.3390/pharmaceutics13081239